Burlingame, Oct. 11, 2024 (GLOBE NEWSWIRE) — CoherentMI published a report, titled, Lambert Eaton Myasthenic Syndrome Market is estimated to value at US$ 0.09 Billion in the year 2024, and is anticipated to reach US$ 1.38 Billion by 2031, with growing at a CAGR of 6.35% during the forecast period 2024-2031.   The Lambert Eaton Myasthenic Syndrome market has been experiencing growth due to rising diagnosis and treatment rates around the world. Lambert Eaton Myasthenic Syndrome is an autoimmune disorder affecting the connection between nerves and muscles. However, it remains quite rare and often underdiagnosed. In recent years, advances in clinical research and diagnostic techniques have helped improve detection of Lambert Eaton Myasthenic Syndrome symptoms. Another major factor spurring market growth is the emergence of novel therapeutic options for Lambert Eaton Myasthenic Syndrome. For many years, treatment was restricted to immune-suppressing medications that carried several side effects. However, newer targeted therapies have now become available that demonstrate higher efficacy with reduced adverse effects.

Market Dynamics:

The Lambert Eaton Myasthenic Syndrome market is driven by increasing research and development activities for developing novel treatment options. Drug makers are investing significantly in R&D to develop targeted immunotherapies with novel mechanisms of action.

For instance, in February 2020, Catalyst Pharmaceuticals initiated Phase III clinical trial to evaluate the efficacy and safety of Firdapse for Lambert-Eaton Myasthenic Syndrome. Moreover, rising cases of Lambert Eaton Myasthenic Syndrome worldwide is also anticipated to boost the market growth during the forecast period. According to Myasthenia Gravis Foundation of America, Lambert-Eaton myasthenic syndrome affects approximately 1 in every 100,000 people.

Insider access to the report awaits! Request for a sample copy of this report

Report Coverage & Scope:

Key Market Takeaways:

• The global Lambert Eaton Myasthenic Syndrome market size is anticipated to witness a CAGR of 6.35% during the forecast period 2024-2031, owing to increasing research & development activities for orphan drugs and rising geriatric population.
• On the basis of type, paraneoplastic segment is expected to hold a dominant position, owing to high prevalence of paraneoplastic form of LEMS.
• By treatment type, medications segment is projected to dominate the market due to wide availability and established efficacy of immunosuppressants and corticosteroids.
• On the basis of route of administration, oral segment holds the largest share and is expected to grow further during the forecast period due to ease of administration.
• Regionally, North America is expected to hold a dominant position over the forecast period, due to well established healthcare infrastructure and presence of major market players.
• Key players operating in the LEMS market include Catalyst Pharmaceuticals, Inc., Grifols, S.A. and Alexion Pharmaceuticals, Inc. These players are focused on expanding their product portfolios through mergers & acquisitions.

Market Trends:

The Lambert Eaton Myasthenic Syndrome market is witnessing trend of collaborations and partnerships between players. Key companies are focusing on partnering with academic institutes and biotechnology companies to strengthen their research capabilities. For instance, in December 2019, BioArctic entered into a multi-target research collaboration with Eisai.

The collaboration aims to develop and commercialize novel treatments for patients with Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. Moreover, emergence of early stage diagnosis is also a key trend in the market. Availability of sensitive diagnostic tests help diagnose the disease at early stages which can improve treatment outcomes. This is expected to contribute to the market growth over the forecast period.

Recent Developments:

• On May 2024, Catalyst Pharmaceuticals has received FDA approval to increase the maximum daily dose of FIRDAPSE (amifampridine) from 80 mg to 100 mg for adults and pediatric patients over 45 kg. This approval provides greater flexibility in treating Lambert-Eaton myasthenic syndrome (LEMS).
• In May 2023 Precigen, Inc received USFDA authorization for an IND application, initiating a Phase 2 study for the PRGN-2009 Off-the-Shelf AdenoVerse immunotherapy combined with pembrolizumab, targeting recurrent or metastatic cervical cancer. This development is crucial as it opens new avenues for similar innovative therapies in the LEMS treatment market.

Discover Lambert Eaton Myasthenic Syndrome Market Trends – Get your access now!

Lambert Eaton Myasthenic Syndrome Market Segmentation:

• By Type
• By Treatment Type
  • Medications
  • Immunosuppressants
  • Corticosteroids
  • Plasmapheresis
  • Intravenous Immunoglobulin (IVIG)
  • Others (Supportive Therapies)
• By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
• By End User
  • Hospitals
  • Specialized Clinics
  • Home Care Settings
  • Academic & Research Institutions
  • Others

Lambert Eaton Myasthenic Syndrome Market Opportunities:

By Type Segment –

The Lambert Eaton Myasthenic Syndrome market is segmented based on type into paraneoplastic, idiopathic and others. The paraneoplastic segment is expected to hold the largest share of around 60% of the total market by 2024. This is majorly due to the high prevalence of paraneoplastic LEMS where symptoms of muscle weakness are associated with an underlying malignancy in majority of cases. According to recent studies, paraneoplastic LEMS accounts for nearly 70-80% of all LEMS cases.

By Treatment Type –

The treatment type segment includes medications, plasmapheresis and supportive therapies. Among these, the medications segment is anticipated to dominate with a share of over 45% by 2024. Within medications, immunosuppressants and corticosteroids are widely used for treatment of LEMS. Plasmapheresis segment includes intravenous immunoglobulin (IVIG) and is expected to witness steady growth during the forecast period.

Finally, the global Lambert Eaton Myasthenic Syndrome market is set to grow moderately till 2031, supported by ongoing research activities and demand for orphan drugs to treat rare diseases.

Purchase Latest Edition of this Research Report @ https://www.coherentmi.com/industry-reports/lambert-eaton-myasthenic-syndrome-market/buynow

Lambert Eaton Myasthenic Syndrome Market Report – Table of Contents:

1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Lambert Eaton Myasthenic Syndrome Market, By Type, 2024-2031, (USD Bn)
5. Global Lambert Eaton Myasthenic Syndrome Market, By Treatment Type, 2024-2031, (USD Bn)
   • Medications
   • Plasmapheresis
   • Intravenous Immunoglobulin (IVIG)
   • Others (Supportive Therapies)
6. Global Lambert Eaton Myasthenic Syndrome Market, By Route Of Administration: 2024-2031, (USD Bn)
   • Oral
   • Intravenous
   • Subcutaneous
7. Global Lambert Eaton Myasthenic Syndrome Market, By End User, 2024-2031, (USD Bn)
   • Hospitals
   • Specialized Clinics
   • Home Care Settings
   • Academic & Research Institutions
   • Others
8. Global Lambert Eaton Myasthenic Syndrome Market, By Region, 2019 – 2031, Value (USD Bn)
   • North America
   • Latin America
   • Europe
   • Asia Pacific
   • Middle East
   • Africa
9. Competitive Landscape
10. Analyst Recommendations
11. References And Research Methodology

Have a Look at Trending Research Reports:

Acute Graft-versus-Host Disease Market: The Global Acute Graft-versus-Host Disease Market is estimated to be valued at USD 3.9 Bn in 2024 and is expected to reach USD 5.9 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.10% from 2024 to 2031.

Cytomegalovirus (CMV) Infection Therapeutic Market: The Global Cytomegalovirus (CMV) Infection Therapeutic Market is estimated to be valued at USD 231.4 Mn in 2024 and is expected to reach USD 370.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.10% from 2024 to 2031.

Alopecia Areata Treatment Market: The Global Alopecia Areata Treatment Market is estimated to be valued at USD 10.51 Bn in 2024 and is expected to reach USD 18.61 Bn by 2031, growing at a compound annual growth rate (CAGR) of 15.10% from 2024 to 2031.

Idiopathic CD4+ Lymphocytopenia Market: The idiopathic CD4+ lymphocytopenia market is estimated to be valued at USD 120.7 Mn in 2024 and is expected to reach USD 204.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.

Author of this marketing PR:

Ravina Pandya, PR Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.

About Us:

At CoherentMI, we are a leading global market intelligence company dedicated to providing comprehensive insights, analysis, and strategic solutions to empower businesses and organizations worldwide. Moreover, CoherentMI is a subsidiary of Coherent Market Insights Pvt Ltd., which is a market intelligence and consulting organization that helps businesses in critical business decisions. With our cutting-edge technology and experienced team of industry experts, we deliver actionable intelligence that helps our clients make informed decisions and stay ahead in today’s rapidly changing business landscape.

Mr. Shah
CoherentMI,
U.S.: +1-650-918-5898
U.K: +44-020-8133-4027
Australia: +61-2-4786-0457
INDIA: +91-848-285-0837
Email: sales@coherentmi.com
Website: https://www.coherentmi.com